Monday, May 5, 2014

The Motley Fool: Is Becton, Dickinson and Company a Buy?

The general theme of med-tech earnings through this cycle seems to be that the market has gotten a little bit ahead of many of the companies, leading to earnings reports that the sell-side characterizes as "slightly disappointing." Among those is Becton Dickinson (NYSE: BDX  ) , a generally reliable company that is structured more for long-term performance than short-term growth. Analysts seem focused on the weak results in diagnostics, but the overall picture hasn't really changed all that much.

Follow this link for the full article:
Is Becton, Dickinson and Company a Buy?

No comments: